Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Fan ST;Fan ST; Edgington TS
  • Source:
    The Journal of clinical investigation [J Clin Invest] 1991 Jan; Vol. 87 (1), pp. 50-7.
  • Publication Type:
    Journal Article; Research Support, U.S. Gov't, P.H.S.
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
      Antigens, CD/*analysis ; Blood Coagulation Factors/*biosynthesis ; Macrophage-1 Antigen/*physiology ; Macrophages/*immunology ; Receptors, Leukocyte-Adhesion/*physiology ; Thromboplastin/*biosynthesis; Animals ; Blood Coagulation Factors/analysis ; CD18 Antigens ; Calcium/physiology ; Factor VII/biosynthesis ; Factor X/metabolism ; Humans ; Lipopolysaccharides/pharmacology ; Mice ; Mice, Inbred Strains
    • Abstract:
      Initiation and regulation of localized selective proteolysis is an important effector property of cells of macrophage (Mo) lineage. Among such effector responses is the induced expression of tissue factor (TF) by cells of Mo lineage. In characterizing the regulation of the Mo responses that may influence the magnitude of the effector phase of the cellular immune response, we have identified a role for the cell surface adhesive receptor CD11b/CD18 (Mac-1, CR3) to amplify the induced TF response. Occupancy of CD11b/CD18 by MAb as surrogate ligands does not directly initiate a TF response. In contrast, after either T cell-derived cytokine or LPS as initial signals, engagement of CD11b/CD18 by MAb induces a two- to eight-fold functional enhancement of the TF response in murine and human Mo. This pathway of CD11b/CD18 enhancement of this Mo effector response was also confirmed with recognized ligands for CD11b/CD18 by exposure of Mo to immobilized fibrinogen. A quantitative increase of Mo surface expression of TF was validated by flow cytometry. We suggest that engagement of CD11b/CD18 by complementary ligands including adherence to extracellular matrix, and possibly in antigen-driven TH:Mo collaborative responses, results in the transduction of cellular signals that quantitatively enhance the expression of TF per se and thereby enhance the inflammatory component of Mo mediated response.
    • References:
      J Immunol. 1985 Dec;135(6):4189-97. (PMID: 2999239)
      J Immunol. 1988 Sep 15;141(6):1819-27. (PMID: 2971715)
      J Immunol. 1986 Nov 15;137(10):3231-9. (PMID: 2945864)
      J Exp Med. 1987 Mar 1;165(3):733-49. (PMID: 3102677)
      J Cell Biol. 1988 Nov;107(5):1893-900. (PMID: 3053736)
      J Exp Med. 1989 Jan 1;169(1):175-83. (PMID: 2462607)
      J Exp Med. 1989 Aug 1;170(2):431-48. (PMID: 2569026)
      Mol Cell Biol. 1989 Jun;9(6):2752-5. (PMID: 2503712)
      Biochemistry. 1989 Feb 21;28(4):1755-62. (PMID: 2719931)
      Thromb Res. 1988 Nov 1;52(3):247-61. (PMID: 3194899)
      J Exp Med. 1984 Dec 1;160(6):1901-18. (PMID: 6096477)
      Immunol Cell Biol. 1987 Apr;65 ( Pt 2):127-39. (PMID: 3301639)
      Annu Rev Med. 1987;38:175-94. (PMID: 3555290)
      J Exp Med. 1986 Oct 1;164(4):1332-7. (PMID: 3531384)
      J Immunol. 1986 Nov 1;137(9):2864-70. (PMID: 3760575)
      J Immunol. 1986 Oct 15;137(8):2585-91. (PMID: 3760568)
      J Clin Invest. 1985 Dec;76(6):2440-5. (PMID: 3935670)
      Cell Immunol. 1990 Jun;128(1):52-62. (PMID: 1971532)
      Biochemistry. 1990 Apr 3;29(13):3413-20. (PMID: 1970743)
      J Immunol. 1990 Apr 1;144(7):2702-11. (PMID: 2181020)
      Blood. 1990 Apr 1;75(7):1481-9. (PMID: 2317559)
      Proc Natl Acad Sci U S A. 1990 Mar;87(6):2254-8. (PMID: 2315317)
      Immunol Rev. 1983;74:29-56. (PMID: 6195085)
      J Immunol. 1982 Jan;128(1):331-6. (PMID: 6172485)
      J Immunol. 1981 Aug;127(2):590-5. (PMID: 6166678)
      J Immunol. 1983 Jun;130(6):2743-9. (PMID: 6189899)
      J Exp Med. 1981 Oct 1;154(4):1150-63. (PMID: 6270227)
      J Immunol. 1985 Oct;135(4):2785-9. (PMID: 3161950)
      J Clin Invest. 1988 Feb;81(2):531-7. (PMID: 2828429)
      J Biol Chem. 1988 May 25;263(15):7007-15. (PMID: 2835359)
      Cell. 1987 Feb 27;48(4):549-54. (PMID: 3028640)
      Proc Natl Acad Sci U S A. 1983 Sep;80(18):5699-703. (PMID: 6225125)
      J Exp Med. 1984 Apr 1;159(4):1042-57. (PMID: 6368733)
      J Clin Invest. 1983 Jul;72(1):171-9. (PMID: 6874946)
      Curr Top Microbiol Immunol. 1978;81:115-20. (PMID: 567555)
      Blood. 1973 Jul;42(1):47-59. (PMID: 4717408)
      J Clin Invest. 1971 Sep;50(9):1819-30. (PMID: 5564389)
      J Cell Biol. 1989 Jul;109(1):389-95. (PMID: 2663880)
      Proc Natl Acad Sci U S A. 1988 Oct;85(20):7462-6. (PMID: 2971972)
      Proc Natl Acad Sci U S A. 1988 Oct;85(20):7734-8. (PMID: 2971974)
      J Cell Biol. 1989 Sep;109(3):1341-9. (PMID: 2475511)
    • Grant Information:
      P01 CA-41085 United States CA NCI NIH HHS
    • Accession Number:
      0 (Antigens, CD)
      0 (Blood Coagulation Factors)
      0 (CD18 Antigens)
      0 (Lipopolysaccharides)
      0 (Macrophage-1 Antigen)
      0 (Receptors, Leukocyte-Adhesion)
      0 (macrophage procoagulant activity)
      9001-25-6 (Factor VII)
      9001-29-0 (Factor X)
      9035-58-9 (Thromboplastin)
      SY7Q814VUP (Calcium)
    • Publication Date:
      Date Created: 19910101 Date Completed: 19910201 Latest Revision: 20181113
    • Publication Date:
      20240829
    • Accession Number:
      PMC294989
    • Accession Number:
      10.1172/JCI115000
    • Accession Number:
      1670636